KalVista Pharmaceuticals
KALV
KALV was delisted on the 10th of June, 2026.
101 hedge funds and large institutions have $349M invested in KalVista Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 34 increasing their positions, 27 reducing their positions, and 9 closing their positions.
165% more call options, than puts
Call options by funds: $10.8M | Put options by funds: $4.06M
89% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 9
26% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 27
13% more capital invested
Capital invested by funds: $310M → $349M (+$39.2M)
9% more funds holding
Funds holding: 93 → 101 (+8)
4.59% more ownership
Funds ownership: 100.82% → 105.42% (+4.6%)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LGM
Logos Global Management
San Francisco,
California
|
+$9.2M |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
+$8.06M |
| 3 |
SVCM
Saturn V Capital Management
Austin,
Texas
|
+$4.07M |
| 4 |
SCM
Suvretta Capital Management
New York
|
+$3.95M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$1.66M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
-$5.02M |
| 2 |
CC
Commodore Capital
New York
|
-$2.81M |
| 3 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$2.25M |
| 4 |
MB
MPM BioImpact
Boston,
Massachusetts
|
-$1.88M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
-$975K |
KALV Hedge Fund Activity: Q3 2023 in Review
101 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in KalVista Pharmaceuticals (KALV) for Q3 2023, worth a combined $349M — up 13% from $310M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new KALV positions and 9 closed out — a net gain of 8 holders — while 34 added to existing stakes and 27 trimmed.
The largest buyer was Logos Global Management, opening a new position worth an estimated $9.2M. The largest seller was Silverarc Capital Management, cutting an estimated $5.02M.
- 101 institutional investors held KalVista Pharmaceuticals (KALV) as of Q3 2023, up from 93 in Q2 2023.
- Funds reported $349M of KalVista Pharmaceuticals stock for Q3 2023, up 13% quarter-over-quarter.
- 17 funds opened new KalVista Pharmaceuticals positions in Q3 2023 and 9 closed out, a net change of +8 holders.
- The largest KalVista Pharmaceuticals buyer in Q3 2023 was Logos Global Management, an estimated $9.2M added.
- The largest KalVista Pharmaceuticals seller in Q3 2023 was Silverarc Capital Management, an estimated $5.02M sold.
Based on aggregated 13F filings for Q3 2023.